175 related articles for article (PubMed ID: 11861305)
1. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.
San Miguel JF; Almeida J; Mateo G; Bladé J; López-Berges C; Caballero D; Hernández J; Moro MJ; Fernández-Calvo J; Díaz-Mediavilla J; Palomera L; Orfao A
Blood; 2002 Mar; 99(5):1853-6. PubMed ID: 11861305
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
[TBL] [Abstract][Full Text] [Related]
3. BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.
Requirand G; Robert N; Boireau S; Vincent L; Seckinger A; Bouhya S; Ceballos P; Cartron G; Hose D; Klein B; Moreaux J
Cytometry B Clin Cytom; 2019 May; 96(3):209-214. PubMed ID: 30417559
[TBL] [Abstract][Full Text] [Related]
4. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.
Paiva B; Vidriales MB; Mateo G; Pérez JJ; Montalbán MA; Sureda A; Montejano L; Gutiérrez NC; García de Coca A; de las Heras N; Mateos MV; López-Berges MC; García-Boyero R; Galende J; Hernández J; Palomera L; Carrera D; Martínez R; de la Rubia J; Martín A; González Y; Bladé J; Lahuerta JJ; Orfao A; San-Miguel JF;
Blood; 2009 Nov; 114(20):4369-72. PubMed ID: 19755674
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.
Liu H; Yuan C; Heinerich J; Braylan R; Chang M; Wingard J; Moreb J
Leuk Lymphoma; 2008 Feb; 49(2):306-14. PubMed ID: 18231918
[TBL] [Abstract][Full Text] [Related]
7. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B; Vídriales MB; Rosiñol L; Martínez-López J; Mateos MV; Ocio EM; Montalbán MÁ; Cordón L; Gutiérrez NC; Corchete L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Granell M; Gorosquieta A; Alegre A; Orfao A; Lahuerta JJ; Bladé J; San Miguel JF;
Leukemia; 2013 Oct; 27(10):2056-61. PubMed ID: 23743858
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.
Rawstron AC; Davies FE; DasGupta R; Ashcroft AJ; Patmore R; Drayson MT; Owen RG; Jack AS; Child JA; Morgan GJ
Blood; 2002 Nov; 100(9):3095-100. PubMed ID: 12384404
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma.
Mateo G; Corral M; Almeida J; López-Berges C; Nieto mJ; García-Marcos A; Vázquez L; del Cañizo C; Orfao A; San Miguel JF
Haematologica; 2003 Sep; 88(9):1013-21. PubMed ID: 12969809
[TBL] [Abstract][Full Text] [Related]
10. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
12. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: The diagnostic utility of defining ranges of normal antigenic expression in comparison to histology.
Cannizzo E; Bellio E; Sohani AR; Hasserjian RP; Ferry JA; Dorn ME; Sadowski C; Bucci JJ; Carulli G; Preffer F
Cytometry B Clin Cytom; 2010 Jul; 78(4):231-8. PubMed ID: 20198608
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotyping of plasma cells in multiple myeloma.
Mateo Manzanera G; San Miguel Izquierdo JF; Orfao de Matos A
Methods Mol Med; 2005; 113():5-24. PubMed ID: 15968091
[TBL] [Abstract][Full Text] [Related]
14. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
[TBL] [Abstract][Full Text] [Related]
15. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
16. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.
Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE
Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351
[No Abstract] [Full Text] [Related]
17. Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression.
Fernández de Larrea C; Tovar N; Rozman M; Rosiñol L; Aróstegui JI; Cibeira MT; Rovira M; Yagüe J; Bladé J
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1084-7. PubMed ID: 21215814
[TBL] [Abstract][Full Text] [Related]
18. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
[TBL] [Abstract][Full Text] [Related]
19. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
[TBL] [Abstract][Full Text] [Related]
20. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.
Landgren O; Owen RG
Cytometry B Clin Cytom; 2016 Jan; 90(1):14-20. PubMed ID: 26147584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
